# Phase Ia/Ib Study of RS-0139 in Patients With a Recurrent, Locally Advanced or Metastatic Solid Tumors

> **NCT04261413** · PHASE1 · COMPLETED · sponsor: **RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S.** · enrollment: 16 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** RS-0139

## Key facts

- **NCT ID:** NCT04261413
- **Lead sponsor:** RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-13
- **Primary completion:** 2026-03-04
- **Final completion:** 2026-03-04
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04261413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04261413, "Phase Ia/Ib Study of RS-0139 in Patients With a Recurrent, Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04261413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*